Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis

Seung Hyeok Han, Ea Wha Kang, Se Jung Yoon, Hyang Sook Yoon, Hyun Chul Lee, Tae Hyun Yoo, Kyu Hun Choi, Dae Suk Han, Shin Wook Kang

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

Background. Statins and angiotensin receptor blockers (ARBs) are known to improve vascular dysfunction in patients with chronic kidney disease. However, these effects have been inconsistent in dialysis patients. Moreover, it is currently unknown whether adding statins to ARBs improves vascular dysfunction better than ARB monotherapy in these patients.Methods. We conducted a prospective open randomized trial to investigate the effects of statin add-on to ARB on vascular protection in 124 nondiabetic patients undergoing peritoneal dialysis (PD). Initially, all patients received 80 mg/day of valsartan for 6 months. Excluding 10 patients who dropped out during this period, patients were randomly assigned to continue ARB treatment alone (n = 57) or to receive 10 mg/day of rosuvastatin (n = 57) added to ARB for the next 6 months. To assess vascular function, endothelium-dependent vasodilation and arterial stiffness were determined by brachial artery flow-mediated dilation (FMD) and brachial-ankle pulse wave velocity (baPWV), respectively.Results. Compared to baseline values, ARB treatment for the first 6 months significantly improved FMD% (2.97 ± 2.64 to 3.57 ± 2.58 %, P < 0.001). In addition, there was a small but significant decrease in baPWV during this period (1691.5 ± 276.3 to 1635.0 ± 278.6 cm/s, P = 0.048). After randomization, add-on treatment further improved FMD% (3.57 ± 2.73 to 4.24 ± 2.77 %, P = 0.003), whereas ARB monotherapy did not (P = 0.02 for between-group difference). Further slight improvement in baPWV (1617.0 ± 280.9 to 1528.9 ± 266.8 cm/s, P = 0.021) was observed only in the combined treatment group (P = 0.28 for between-group difference).Conclusions. Adding a statin to the ARB was of some help in improving vascular dysfunction more effectively than ARB monotherapy in nondiabetic PD patients. However, whether such limited improvements can lead to better clinical outcomes requires further investigation.

Original languageEnglish
Pages (from-to)3722-3728
Number of pages7
JournalNephrology Dialysis Transplantation
Volume26
Issue number11
DOIs
Publication statusPublished - 2011 Nov

Bibliographical note

Funding Information:
Acknowledgements. This work was supported by the Yonsei University (Brain Korea 21) Project for Medical Sciences, a grant from the Korea Science and Engineering Foundation funded by the Korean government (MOST) (R13-2002-054-04001-0) and a grant of the Korea Healthcare Technology R&D Project of the Ministry for Health, Welfare & Family Affairs, Republic of Korea (A084001).

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Transplantation

Fingerprint

Dive into the research topics of 'Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis'. Together they form a unique fingerprint.

Cite this